To the Editor:
The first successful allogeneic peripheral blood progenitor cell (allo-PBSC) transplantations in patients with leukemia and lymphoma have been reported./' A posttransplant follow-up of 19 months is indicative of a functioning and sustained self-renewal capacity of allografted blood stem cells.' Meanwhile, as confirmed by various studies: acute graft-versus-host disease (GVHD) has not been observed to develop at an increased rate or more severely in those patients, despite the fact that an additional log of donor-derived immunocompetent cells had been transplanted. ' Thus, it is foreseeable in the near future to include matched, unrelated donors into an allogeneic blood stem cell transplantation program with the possible donor-related advantages of (1) no use of general anesthesia for stem cell harvest, (2) easy and multiple access to the circulating stem cell pool, (3) higher yields of hematopoietic progenitor cells, and (4) no need for exact timing of blood stem cell donation and transplantation.
With cytokine mobilization treatment, one to three consecutive daily aphereses are sufficient to collect a safe CD34+ cell en-
Anderson Cancer Center, stem cells are peripheralized using granulocyte colony-stimulating factor (G-CSF) at a dose of 6 pg/kg subcutaneously every 12 hours, starting 3 days before the first apheresis (day 4). G-CSF treatment of normal donors is considered safe, and is routinely used for granulocyte collections.* In a series of 62 normal donors undergoing stem cell aphereses for their HLA-matched sibling, the mean yield of CD34' cells collected per kg,,,,,,,,,, and per liter of donor blood processed was 5 I X 1 04.
With L5 L of donor blood processed per apheresis (equivalent to about three times the donor's blood volume), a mean total of 7.65 X 106 CD34' cells/kg~cc,pie,~t can be expected to be harvested by a single apheresis, which is significantly higher than the safe allogeneic engraftment dose of 4 X IO6 CD34' cells per kg,,,,,,,,,,.' Based on such preliminary allo-PBSC transplantation experience in a few major transplant centers in the United States and Western Europe, the inclusion of matched, unrelated donors donating stem cells by single or tandem apheresis seems to be an attractive option, being favorable to potential volunteer, unrelated donors undergoing multiple bone marrow aspirations under general anesthesia.
As of April 1994, the National Marrow Donor Program (NMDP) in the United States encompasses l .2 million volunteer marrow donors typed for HLA A, B, of which only 17% are minority volunteer donors. The inclusion of typed apheresis donors would extensively expand the availability of matched, unrelated stem cell donors, particularly in minorities. Apheresis-derived mononuclear cells, fi-ozen and stored in a blood bank, can be made available independently from the conditioning regimen delivered to the potential blood stem cell recipient. Frozen apheresis products are easily shipped and thawed for intravenous infusion when needed, whereas, freshly donated martow needs meticulous timing between the marrow harvesting team, transportation facilities, and transplantation team. One could even preferentially store and accumulate uncommon HLA types over many years on a prophylactic basis, without significant loss of stem cell viability. A larger storage volume of frozen apheresis products could be overcome by concentration of progenitor cells before freezing, using an inexpensive single step density gradient' performed in a blood cell processor machine (COBE 2991 ; COBE BCT, Inc, Lakewood, CO).
Finally, the age limit for volunteer stem cell donation can be expanded up to 77 years (personal observation, May 1995), and probably higher with unimpaired CD34' cell mobilization capability. This age group is usually not eligible for a multiple bone marrow aspiration procedure under general anesthesia. Thus, one can foresee that volunteer blood stem cell donation under the control of The American Association of Blood Banks, Food and Drug Administration, and NMDP will become an easy and well-accepted apheresis procedure as for any other blood component donations, such as platelets and granulocytes.
